ADCT vs. ARDX, TWST, VERA, AVDL, COGT, SNDX, JANX, SDGR, HROW, and AMPH
Should you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Ardelyx (ARDX), Twist Bioscience (TWST), Vera Therapeutics (VERA), Avadel Pharmaceuticals (AVDL), Cogent Biosciences (COGT), Syndax Pharmaceuticals (SNDX), Janux Therapeutics (JANX), Schrodinger (SDGR), Harrow (HROW), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry.
ADC Therapeutics vs. Its Competitors
Ardelyx (NASDAQ:ARDX) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.
Ardelyx presently has a consensus price target of $11.70, suggesting a potential upside of 79.17%. ADC Therapeutics has a consensus price target of $7.75, suggesting a potential upside of 141.81%. Given ADC Therapeutics' higher possible upside, analysts plainly believe ADC Therapeutics is more favorable than Ardelyx.
Ardelyx has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500.
In the previous week, Ardelyx had 6 more articles in the media than ADC Therapeutics. MarketBeat recorded 10 mentions for Ardelyx and 4 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 1.45 beat Ardelyx's score of 1.31 indicating that ADC Therapeutics is being referred to more favorably in the news media.
Ardelyx has a net margin of -14.60% compared to ADC Therapeutics' net margin of -220.00%. ADC Therapeutics' return on equity of 0.00% beat Ardelyx's return on equity.
Ardelyx has higher revenue and earnings than ADC Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 4.8% of Ardelyx shares are owned by company insiders. Comparatively, 5.4% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Ardelyx beats ADC Therapeutics on 10 of the 17 factors compared between the two stocks.
Get ADC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADC Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:ADCT) was last updated on 9/15/2025 by MarketBeat.com Staff
Free ADCT Stock Alerts